Search Dental Tribune

Bredent medical launches new generation of whiteSKY zirconia implants

E-Newsletter

The latest news in dentistry free of charge.

  • This field is for validation purposes and should be left unchanged.
Zirconia is perfectly suited for implants since its strength is comparable with that of titanium and it exhibits ideal elasticity and long-term resistance to fracture. (Image: bredent)
bredent

By bredent

Tue. 1 March 2022

save

LONDON, UK: The whiteSKY ceramic implant system from bredent medical has been on the market for more than 15 years, and its reliability has been demonstrated in numerous studies and in practice. The system has now been extended with the new one-piece whiteSky Tissue Line, which is versatile and suitable for a wide range of indications, including single restorations in the aesthetic zone and short-span bridges in the premolar and molar region.

Depending on the competence of the dental team, the new generation of whiteSKY can be used for very challenging cases, if the right prosthetic concept is developed. It is available in different diameters and lengths.

The first generation of whiteSKY implants, that was introduced in 2006, is one of the best-documented zirconia implant systems available to clinicians. Clinical and scientific evaluations, including histological investigations, confirming the implant’s excellent osseointegration and verified long-term clinical outcomes were carried out from the beginning. Research has shown that its survival rate is on par with that of titanium implants, that bone levels are stable in the long term and that it provides outstanding aesthetic results.1,2 Furthermore, studies have shown that ceramic dental implants in general exhibit good biocompatibility, epithelial attachment and low plaque accumulation.3 They are a reliable alternative to titanium implants for patients with metal allergies.

Commenting on his use of whiteSKY, Dr Claude Gallizia from France stated: “When I started managing patients with whiteSKY, it quickly became a win-win situation. The system was simpler to use and also cheaper than other zirconia implant systems. I have completely stopped using titanium implants, as my patients now happily pay a little extra for zirconia.” He continued: “I am pleased to say that, with whiteSKY, we find minimal post-operative pain, achieve beautiful osseointegration and get a phenomenal reaction with hard and soft tissues. Thanks to whiteSKY, I have been able to increase the number of patients I treat with implants. The bredent system allows for a very gentle process with minimal or no emergencies. From a business viewpoint, whiteSKY is definitely an asset for my practice. Patients enjoy beautiful results, and consequently, I have more patients enquiring about it.”

Dr Luis Lapa Bessa from Portugal summarised the advantages of the implant system as follows: “The main advantage for me with whiteSKY is that it can address a thin tissue biotype, and this is important because it has a significant impact on the outcome of restorative and regenerative therapy. WhiteSKY works very well and does not require more tissue to cover the implant. The second main advantage is that, in 90% of cases, we are aiming for immediate loading, which makes it important to have an implant which addresses both aesthetic and function at the same time. As a result, we have happy patients who spend less time in the chair and appreciate a minimally invasive treatment. In one appointment, we are normally able to resolve almost everything.”

More information can be found at www.bredent-implants.com.

Editorial note:

References

  1. Borgonovo, A. E. et al. (2021). A clinical and radiographic evaluation of zirconia dental implants: 10-year follow-upInternational Journal of Dentistry, 2021.
  2. Steyer, E. et al. (2021). Immediate restoration of single-piece zirconia implants: a prospective case series—long-term results after 11 years of clinical function. Materials, 14(22).
  3. Depprich, R. et al. (2008). Osseointegration of zirconia implants compared with titanium: an in vivo studyHead & Face Medicine, 4(30).

Leave a Reply

Your email address will not be published. Required fields are marked *

-